精彩内容近日,复星医药旗下上海朝晖药业的盐酸苯海拉明注射液通过一致性评价,为首家过评,截至目前集团(含子公司)已过评/视同过评的产品超过170个。盐酸苯海拉明注射液是全身用抗组胺药热销产品,2024年在中国三大终端六大市场的销售额已涨至1.6亿元。图1:复星医药获批的产品情况来源:国家药监局官网图2:盐酸苯海拉明注射液的批文情况来源:米内网中国上市药品(MID)数据库盐酸苯海拉明注射液是一种乙醇胺...
Source Link精彩内容近日,复星医药旗下上海朝晖药业的盐酸苯海拉明注射液通过一致性评价,为首家过评,截至目前集团(含子公司)已过评/视同过评的产品超过170个。盐酸苯海拉明注射液是全身用抗组胺药热销产品,2024年在中国三大终端六大市场的销售额已涨至1.6亿元。图1:复星医药获批的产品情况来源:国家药监局官网图2:盐酸苯海拉明注射液的批文情况来源:米内网中国上市药品(MID)数据库盐酸苯海拉明注射液是一种乙醇胺...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.